{"product_id":"cdk6-antibody-sc-f0372","title":"CDK6 Antibody","description":"\u003ch2\u003eAbout the Target\u003c\/h2\u003e\u003cp\u003eThe gene encoding cyclin-dependent kinase 6 (CDK6) is situated on human chromosome 7 and encodes a kinase comprising 326 amino acids. Cyclin-dependent kinases form complexes with cyclin partners as well as CDK inhibitors. CDK6 and CDK4 team up with D-type cyclins to phosphorylate the retinoblastoma protein, facilitating progression through the G1\/S phase checkpoint.\u003c\/p\u003e\u003cp\u003eReported cellular context includes cell projection, cytoplasm, cytoskeleton, and nucleus, which can matter when signal is compared across treatments or changing cell states. Following CDK6 across matched perturbations can help separate abundance effects from shifts in localization, complex assembly, or pathway state.\u003c\/p\u003e\u003ch2\u003eResearch Context\u003c\/h2\u003e\u003cp\u003eCDK6 is commonly interpreted in the context of cancer and cell cycle research, and readouts are often stronger when a study separates expression changes from compartment-level redistribution. When reported signal spans cell projection, cytoplasm, and cytoskeleton, a defined reference condition can make comparisons more interpretable across perturbations, passages, or replicate sets.\u003c\/p\u003e\u003cp\u003eConsider these angles when interpreting target-level changes:\u003c\/p\u003e\u003cul\u003e\n\u003cli\u003eapparent redistribution between cell projection, cytoplasm, and cytoskeleton across matched conditions\u003c\/li\u003e\n\u003cli\u003echanges associated with proliferative state, oncogenic signaling, or treatment response\u003c\/li\u003e\n\u003cli\u003ecell-cycle linked differences in abundance, timing, or compartmental enrichment\u003c\/li\u003e\n\u003cli\u003eco-patterning with orthogonal markers and control conditions that clarify pathway state\u003c\/li\u003e\n\u003c\/ul\u003e\u003ch2\u003eVariant Considerations\u003c\/h2\u003e\u003cp\u003eIf your project spans exploratory questions, the regular version offers a balanced option for establishing baseline signal behavior for CDK6. This can help when protocols evolve over time and the goal is to compare experiments using a stable reference workflow.\u003c\/p\u003e\u003cp\u003eStandardize sampling time, control choice, and downstream analysis thresholds so apparent differences in CDK6 reflect biology rather than handling. When interpreting CDK6, it is often useful to decide early whether the main question is overall abundance, compartmental enrichment, or context-dependent redistribution.\u003c\/p\u003e\u003cp\u003eFor multi-run studies, a shared reference condition can keep CDK6 trends easier to compare across datasets. That kind of consistency is especially helpful when follow-up work expands to new perturbations, model systems, or longitudinal collections.\u003c\/p\u003e","brand":"Selleck Chemicals","offers":[{"title":"20 µl","offer_id":57577447817561,"sku":"F0372-20UL","price":139.0,"currency_code":"EUR","in_stock":true},{"title":"100 µl","offer_id":57577447850329,"sku":"F0372-100UL","price":319.0,"currency_code":"EUR","in_stock":true},{"title":"2 × 100 µl","offer_id":57577447883097,"sku":"F0372-2X100UL","price":479.0,"currency_code":"EUR","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0923\/1011\/0553\/files\/F0372-wb.gif?v=1773598388","url":"https:\/\/absource.de\/products\/cdk6-antibody-sc-f0372","provider":"Absource Diagnostics","version":"1.0","type":"link"}